GlassScriptPhysician profile
Albert Lester Sprinkle
NPI 1841337664
$4,270.22
in general payments reported to CMS, 2019-2025
22 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $361 · 2021: $777 · 2022: $635 · 2023: $1,081 · 2024: $667 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,106.23 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $727.82 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $658.09 | 2019-2024 | Jornay Pm |
| Abbvie INC. | $615.42 | 2021-2024 | Vraylar |
| Supernus Pharmaceuticals, INC. | $594.99 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $345.26 | 2020-2024 | Dyanavel Xr |
| Neos Therapeutics, LP | $306.70 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $245.72 | 2020-2022 | |
| Lundbeck LLC | $143.94 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $122.70 | 2019-2024 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $113.86 | 2023-2024 | Auvelity |
| Allergan, INC. | $76.43 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.88 | 2022-2023 | |
| Shire North American Group INC | $55.25 | 2019 | |
| Adlon Therapeutics L.P. | $33.71 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $30.38 | 2025 | Jornay Pm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $30.22 | 2025 | Invega Trinza, Invega Sustenna |
| Neurocrine Biosciences, INC. | $23.86 | 2022 | |
| Vertical Pharmaceuticals, LLC | $22.41 | 2024 | Relexxii |
| Arbor Pharmaceuticals, INC. | $15.63 | 2019 | |
| Noven Therapeutics, LLC | $14.68 | 2024 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $14.44 | 2024 | Austedo Xr |
| Neuronetics, INC. | $13.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Sprinkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.